0
Abstract: Poster Presentations |

BRONCHIAL THERMOPLASTY IMPROVES ASTHMA STATUS OF MODERATE-TO-SEVERE PERSISTENT ASTHMATICS OVER AND ABOVE CURRENT STANDARD-OF-CARE FREE TO VIEW

Adalberto Rubin, MD, PhD*; Michel Laviolette, MD; Neil Thomson, MD; Robert Niven, MD; Paul Corris, MD; Hans Siersted, MD; Ron Olivenstein, MD; Ian Pavord, MD; David McCormack, MD; Gerard Cox, MD; John Miller, MD
Author and Funding Information

Santa Casa de Porto Alegre, Porto Alegre, Brazil



Chest. 2006;130(4_MeetingAbstracts):162S. doi:10.1378/chest.130.5.1433
Text Size: A A A
Published online

Abstract

PURPOSE: Bronchial Thermoplasty, a novel therapeutic bronchoscopic procedure that reduces the amount of airway smooth muscle, has the potential to decrease asthma symptoms due to bronchoconstriction. The effects of Bronchial Thermoplasty on the asthma status of subjects taking inhaled corticosteroids (ICS ≥200μg beclomethasone or equivalent) and long-acting β2-agonists (LABA) as maintenance asthma medications were evaluated in a randomized, multicenter clinical trial.

METHODS: 108 subjects taking the required asthma maintenance medications with Pre-BD FEV1 ≥60% and ≤85% predicted, and methacholine PC20 <8mg/mL were enrolled at 10 centers. The Control group (n=53) received standard medical management alone, and the Bronchial Thermoplasty group (n=55) received standard medical management + Bronchial Thermoplasty. Asthma status was assessed 12-weeks post-treatment by comparing the differences between the groups in the changes from Baseline of various asthma-related parameters.

RESULTS: The Bronchial Thermoplasty group showed an improvement over the Control group in the following parameters (values are means±SD for BT versus Control): amPEF: 23.84 ± 40.46(n=46) versus 1.59 ± 32.11(n=44) L/min, p=0.005; pmPEF: 25.03 ± 37.23(n=45) versus 2.52 ± 30.11(n=44) L/min, p=0.002; Symptom-Free-Days (absolute change from Baseline in %SFD): 20.86 ± 34.68(n=46) versus 6.41 ± 34.57(n=45), p=0.05; Puffs of rescue-medication used over 7 days: -3.44 ± 12.10(n=46) versus 0.44 ± 11.98(n=44), NS; AQLQ score: 0.47 ± 0.94(n=50) versus 0.01 ± 0.90(n=46), p=0.016; ACQ score: −0.29 ± 0.78(n=52) versus −0.01 ± 0.68(n=47), p=0.064. Pre- or Post-BD FEV1 values were unchanged.

CONCLUSION: Bronchial Thermoplasty in asthmatic subjects results in a significant improvement in their asthma status over and above the current standard-of-care, three months following the intervention.

CLINICAL IMPLICATIONS: The results suggest that in subjects with moderate to severe persistent asthma taking current standard-of-care maintenance medication, a single intervention with Bronchial Thermoplasty may provide significant clinical benefit.

DISCLOSURE: Adalberto Rubin, Other The AIR Trial was funded by Asthmatx, Inc. All payments were made directly to participating Institutions, and not to the Investigators; Product/procedure/technique that is considered research and is NOT yet approved for any purpose, Bronchial Thermoplasty for asthma.

Wednesday, October 25, 2006

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543